SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

Shuqui Qin; Jin Li; Aiping Zhou; Yanqiao Zhang; Xianglin Yuan; Liangjun Zhu; Baoli Qin; Shan Zeng; Lin Shen; Ying Yuan; Weibo Wang; Jun Liang; Xianwen Zhang; Feng Ye; Ping Chen; Huaizhang Wang; Zhenyan Yu; Lu Yue; Yong Fang; Jianping Xiong; Jianwei Yang; Yiye Wan; Xianli Yin; Wenling Wang; Nong Xu; Xiaohong Wang; Zemin Xiao; Huafang Su; Ying Wang; Kangsheng Gu; Shuiping Tu; Zishu Wang; Bo Liu; Xiaohua Hu; Weixian Liu; Xiaofeng Li

doi:10.1002/cac2.12586

SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

Cancer Commun (Lond). 2024 Aug;44(8):910-914. doi: 10.1002/cac2.12586. Epub 2024 Jul 8.

Authors

Shuqui Qin¹, Jin Li², Aiping Zhou³, Yanqiao Zhang⁴, Xianglin Yuan⁵, Liangjun Zhu⁶, Baoli Qin⁷, Shan Zeng⁸, Lin Shen⁹, Ying Yuan¹⁰, Weibo Wang¹¹, Jun Liang¹², Xianwen Zhang¹³, Feng Ye¹⁴, Ping Chen¹⁵, Huaizhang Wang¹⁶, Zhenyan Yu¹⁷, Lu Yue¹⁸, Yong Fang¹⁹, Jianping Xiong²⁰, Jianwei Yang²¹, Yiye Wan²², Xianli Yin²³, Wenling Wang²⁴, Nong Xu²⁵, Xiaohong Wang²⁶, Zemin Xiao²⁷, Huafang Su²⁸, Ying Wang²⁹, Kangsheng Gu³⁰, Shuiping Tu³¹, Zishu Wang³², Bo Liu³³, Xiaohua Hu³⁴, Weixian Liu³⁵, Xiaofeng Li³⁶

Affiliations

¹ Department of Oncology, Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, P. R. China.
² Department of Medical Oncology, Shanghai East Hospital, Shanghai, P. R. China.
³ Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China.
⁴ Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
⁵ Department of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
⁶ Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China.
⁷ Department of Gastroenterology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.
⁸ Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
⁹ Department of Medical Oncology, Beijing Cancer Hospital, Beijing, P. R. China.
¹⁰ Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
¹¹ Department of Chemotherapy, Shandong Provincial Hospital, Jinan, Shandong, P. R. China.
¹² Department of Medical Oncology, Peking University International Hospital, Beijing, P. R. China.
¹³ Department of Medical Oncology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, P. R. China.
¹⁴ Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, P. R. China.
¹⁵ Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, P. R. China.
¹⁶ Department of Integrated Chinese and Western Medicine, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
¹⁷ Department of Medical Oncology, Mudanjiang Tumor Hospital, Mudanjiang, Heilongjiang, P. R. China.
¹⁸ Department of Oncology, Qingdao Municipal Hospital (Group), Qingdao, Shandong, P. R. China.
¹⁹ Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
²⁰ Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P. R. China.
²¹ Department of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China.
²² Department of Gastroenterology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, P. R. China.
²³ Department of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.
²⁴ Department of Abdominal Oncology, The Affiliated Hospital of Guizhou Medical University, Guizhou, Guizhou, P. R. China.
²⁵ Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
²⁶ Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.
²⁷ Department of Oncology, The First People's Hospital of Changde City, Changde, Hunan, P. R. China.
²⁸ Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.
²⁹ Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
³⁰ Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
³¹ Department of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
³² Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P. R. China.
³³ Department of Gastroenterology, Shandong Cancer Hospital & Institute, Jinan, Shandong, P. R. China.
³⁴ Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.
³⁵ Department of Medical Oncology, Binzhou People's Hospital, Binzhou, Shandong, P. R. China.
³⁶ Department of Medical Oncology, Quanzhou First Hospital, Quanzhou, Fujian, P. R. China.

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / pathology
Female
Humans
Irinotecan* / administration & dosage
Irinotecan* / therapeutic use
Male
Middle Aged
Neoplasm Metastasis
Prospective Studies
Quinazolines* / administration & dosage
Quinazolines* / therapeutic use
Registries*
Thiophenes

Substances

Irinotecan
raltitrexed
Quinazolines
Thiophenes